Nevertheless, these results suggest that surviving OSA patients are mounting a robust, systemic immune response as reflected through elevated levels of a biomarker (APO-TCN2) previously associated with active lymphoproliferative autoimmune disease. Here, TCN2 is linked to obstructive sleep apnea syndrome.